Zentalis Pharmaceuticals, Inc. (ZNTL) Risk Assessment & Volatility Analysis

Comprehensive risk assessment and volatility analysis for ZNTL including beta analysis, market risk, financial risk, and investment risk evaluation. Understand the potential risks and rewards of investing in ZNTL stock with expert risk management insights.

Risk Assessment Summary

High market volatility (Beta > 1.5)

High short interest

High price volatility

Low debt levels

Governance Risk

Overall Risk Score

N/A

Audit Risk

N/A

Board Risk

N/A

Compensation Risk

N/A

Shareholder Rights Risk

N/A

Market Risk

Beta (5Y Monthly)

1.75High

52-Week Change

-60.93%Low

S&P 500 52-Week Change

13.26%Very High

Short Interest Ratio

6.73Very High

Short % of Float

8.78%Very High

Volatility (Annualized)

87.51%Very High

Financial Risk

Total Debt

$40.46M

Enterprise Value

$-136921392.00

Profit Margins

0.00%Very High

Earnings Growth (QoQ)

N/A

Net Income to Common

$-149316000.00

Book Value

$3.50

Risk vs Reward Analysis

Risk Factors

Beta: 1.75

Volatility: 87.51%

Short Interest: 6.73

Potential Rewards

52-Week Change: -60.93%

Earnings Growth: N/A

Profit Margin: 0.00%